Combinatorial chemoprevention of intestinal neoplasia

Christopher J. Torrance, Peta E. Jackson, Elizabeth Montgomery, Kenneth W. Kinzler, Bert Vogelstein, Allan Wissner, Maria Nunes, Philip Frost, Carolyn M. Discafani

Research output: Contribution to journalArticlepeer-review

Abstract

A combination of two drugs afforded remarkable protection from intestinal neoplasia in APC(Min/+) mice, a murine model of human familial adenomatous polyposis (FAP). One of the drugs was sulindac, a prototypical non-steroidal anti-inflammatory drug with established chemopreventative activity. The second drug was EKI-569, a newly developed, irreversible inhibitor of the epidermal growth factor receptor kinase. Although 100% of the untreated APC(Min/+) mice developed ~20 polyps, nearly half the mice treated with these two agents developed no polyps at all. These results suggest a powerful strategy for the chemoprevention of human colonic neoplasia.

Original languageEnglish (US)
Pages (from-to)1024-1028
Number of pages5
JournalNature medicine
Volume6
Issue number9
DOIs
StatePublished - Sep 2000

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'Combinatorial chemoprevention of intestinal neoplasia'. Together they form a unique fingerprint.

Cite this